HIV & gay and bi men — the full picture, 40 years in.

Gay, bisexual, and other men who have sex with men have been at the center of HIV in the United States since before the virus had a name — first as the people dying, then as the people who forced the research, the drugs, and the language to change. Four decades later both halves of that sentence are still true. Male-to-male sexual contact accounted for 25,129 of the 38,793 HIV diagnoses reported among people aged 13 and older in 2024 — about 65% of the national total.1 And nearly every prevention tool now used worldwide, from combination therapy to twice-yearly injectable PrEP, was proven in trials that gay and bi men volunteered for.

This page is the full picture, not the scary version. Gay and bi men are disproportionately affected because of network effects and structural inequities — how sexual networks are shaped, how insurance and clinics are distributed, how criminalization and stigma push people away from testing — not because of anything inherent to who they are or what they do.

You will also find the thing the statistics never lead with: an HIV diagnosis in 2026, treated, means a normal life expectancy and zero risk of passing the virus to a sexual partner. That is not encouragement. That is measured, replicated evidence from tens of thousands of condomless sex acts, and it changes what this diagnosis means for your body, your relationships, and your future.

The numbers — what the 2024 surveillance data actually shows

CDC's national surveillance for 2024 counted 38,793 new HIV diagnoses among people aged 13 and older in the United States and its territories, a rate of 13.3 per 100,000. Males accounted for 30,975 of those — 80% of the total — and male-to-male sexual contact was the transmission category for 25,129 diagnoses, roughly 65% of everything reported.1 Estimates of new infections (a different measure, modeled rather than counted) put the share among gay and bi men at about 67% of the roughly 31,800 new infections in 2022.3

Three patterns inside those totals matter more than the headline.

The epidemic is Southern

Half of all diagnoses attributed to male-to-male sexual contact in 2024 were among men living in the South, and the South accounted for 19,785 diagnoses overall — 51% of the national total, in a region with about 38% of the U.S. population.1 This is a map of Medicaid expansion, clinic density, transportation, and sex education as much as anything else. Our HIV in the South page goes deeper.

It is young, and it is racialized differently by age

People aged 25–34 accounted for 14,183 diagnoses in 2024 — 37% of the total — and ages 25–44 together made up about 60%.1 Within male-to-male sexual contact, the racial pattern shifts sharply with age: among males aged 13–24, 47% of diagnoses were among Black men; among males older than 24, 40% were among Hispanic/Latino men.1 Two different equity failures are stacked inside one statistic, and they need different fixes. See HIV in Black communities and HIV in Latino communities.

Progress is real but uneven

Diagnoses among gay and bi men overall held roughly stable from 2018 through 2022,2 while modeled new infections among gay and bi men fell about 10% over the same period.3 Underneath that average, declines have been concentrated among younger White men, while diagnoses among Hispanic/Latino gay and bi men rose. Meanwhile 1,158,701 people were living with diagnosed HIV in the United States at the end of 2024, 896,231 of them male — a population that is aging into its fifties, sixties, and seventies.1 HIV-related deaths totaled 4,296.1

A word about "lifetime risk"

You will still see the figure that 1 in 6 gay and bi men in the U.S. will be diagnosed with HIV in their lifetime — including 1 in 2 Black gay and bi men, 1 in 4 Latino gay and bi men, and 1 in 11 White gay and bi men.4 Read it for what it is: a projection built on the diagnosis rates of a decade ago, published before PrEP was widely available and before U=U was proven. Updated modeling puts the numbers meaningfully lower. It is a measure of how badly the system was failing, not a prophecy about your life.

Forty years in — GMHC, the Denver Principles, ACT UP

You cannot read the numbers honestly without the history, because the history explains why the tools exist at all.

In 1981, healthy young gay men in New York and Los Angeles began turning up with pneumonia and rare cancers that should not have been possible in their age group. There was no test, no treatment, and no name. Gay Men's Health Crisis was founded in a living room in New York in 1982 — the first community AIDS service organization in the world — because no government agency was coming. Volunteers answered a hotline from an apartment, delivered meals, sat with people who were dying, and buried friends whose families would not.

In June 1983, a group of people with AIDS gathered at a health conference in Denver and wrote a document that reorganized medicine's relationship to the people it treats. The Denver Principles open by refusing the vocabulary being used about them:

The document went on to demand that people with AIDS be involved at every level of decision-making, serve on the boards of the organizations serving them, choose their own representatives and their own agenda, and be included in every AIDS forum with equal credibility.5 Every "nothing about us without us" principle in global health traces to that page. So does the person-first language on this website.

By 1987, deaths were accelerating and the federal response was still glacial. Playwright Larry Kramer — who had helped found GMHC and then broken with it over tactics — gave a speech at New York's Lesbian and Gay Community Services Center that ended with the founding of ACT UP, the AIDS Coalition to Unleash Power. What followed was one of the most effective patient-advocacy campaigns in medical history: activists learned the pharmacology, occupied the FDA, forced parallel-track access to experimental drugs, rewrote how clinical trials enrolled and reported, and pushed the Ryan White CARE Act into law in 1990. Read more on our ACT UP history and Larry Kramer pages.

Two things are worth holding at once. Effective combination therapy arrived in 1996, and the death rate fell off a cliff — a survival line no one in 1987 believed they would see. And an entire generation of gay and bi men did not make it there. The men who are long-term survivors today are living with grief that has no cultural container, alongside the ordinary medical business of aging. Our long-term survivors page is for them.

U=U — the evidence, and what zero actually means

Undetectable equals untransmittable. It is the single most consequential fact in HIV in the last twenty years, and for gay and bi men specifically, the evidence is about as strong as clinical evidence gets.

PARTNER and PARTNER2

The PARTNER study followed mixed-status couples in which the partner living with HIV was on suppressive antiretroviral therapy and the couple reported condomless sex. Its second phase, PARTNER2, was designed specifically to answer the question for gay men, because the first phase had enrolled mostly heterosexual couples. Published in The Lancet in 2019, it enrolled 972 gay male couples, of whom 782 contributed 1,593 eligible couple-years of follow-up covering an estimated 76,088 condomless anal sex acts.6

Fifteen men in the study acquired HIV during follow-up. Genetic sequencing showed that none of the fifteen infections came from the partner in the study — every one was phylogenetically unlinked, acquired from an outside partner. The within-couple transmission rate was zero, with an upper 95% confidence bound of 0.23 per 100 couple-years.6 Translated: even at the very edge of statistical uncertainty, that is roughly one transmission per 435 years of condomless sex. The investigators estimated the ART use in the cohort had prevented around 472 transmissions.6

Opposites Attract

Replication matters, and it exists. Opposites Attract, published in The Lancet HIV in 2018, followed 343 mixed-status male couples in Australia, Brazil, and Thailand across 588.4 couple-years. Participants reported about 16,800 condomless anal sex acts, including 12,447 in which the partner living with HIV had an undetectable viral load and the HIV-negative partner was not taking PrEP. Zero linked transmissions. Three men acquired HIV from partners outside the relationship.7

What this changes in ordinary life is enormous and still under-communicated. It means a person living with HIV can have condomless sex with a partner who does not have HIV without transmitting it. It means mixed-status couples can conceive, parent, and grow old. It means the fear that organized an entire generation's sex lives is, medically, obsolete for people who are suppressed. And it means that "treatment as prevention" is not a slogan — it is the reason expanding care access is a prevention strategy, not just a compassion strategy.

PrEP in 2026 — four options, not one

For most of PrEP's history there was one real choice: a daily pill. There are now four, and all four are prevention for people who do not have HIV. None of them is a treatment, and none of them is a cure.

Doxy-PEP — the STI companion

PrEP prevents HIV, not syphilis, gonorrhea, or chlamydia — and bacterial STIs have been climbing among gay and bi men for a decade. In June 2024, CDC issued formal clinical guidelines for doxycycline post-exposure prophylaxis: a single 200 mg dose of doxycycline taken as soon as possible and within 72 hours after oral, vaginal, or anal sex, not exceeding 200 mg in any 24-hour period. The evidence base showed reductions of more than 70% for syphilis and chlamydia and roughly 50% for gonorrhea. CDC recommends counseling about it for gay and bi men and transgender women who have had a bacterial STI in the previous 12 months.12

It is not for everyone, and antimicrobial-resistance monitoring is an open question. But if you have had syphilis or rectal chlamydia in the past year and nobody has mentioned doxy-PEP to you, start that conversation. Full detail on our PrEP page.

Chemsex — what it is, what it isn't, and harm reduction that works

Chemsex refers to the intentional use of specific drugs — most often crystal methamphetamine, mephedrone, and GHB/GBL — to facilitate or enhance sex, typically between men, often over sessions lasting many hours or several days. The term came out of the community itself, and the first serious qualitative research came out of South London.

Bourne and colleagues interviewed 30 gay men aged 21 to 53 across Lambeth, Southwark, and Lewisham. What they described was not a moral collapse. It was pleasure, connection, escape from shame, and relief from the awkwardness of sober sex — alongside genuine harms, including a striking finding that men newer to these drugs frequently had poor understanding of dosing, particularly with GHB/GBL, where the gap between a recreational dose and an overdose is very small.13

The evidence on whether chemsex independently drives HIV acquisition is genuinely contested, and a 2022 Lancet HIV review says so plainly: causal claims are difficult, the harms extend well beyond HIV — intoxication, overdose, injection-related risk, sleep deprivation, mental-health crises, and the aftermath of consent violations — and the field urgently needs interventions built with the community rather than imposed on it, covering the period before, during, and after a session.14 Prevalence is meaningful but not universal: in surveys of men living with diagnosed HIV in London, roughly a third reported using one of the core chemsex drugs in the previous month.

Mental health — minority stress, depression, and the cost of hiding

Mental health is not a footnote to HIV care for gay and bi men; it is often the thing determining whether the rest of the care works. A meta-analysis of 18 studies including 7,653 men who have sex with men living with HIV found a pooled depression prevalence of 43%, with significantly higher odds than among gay and bi men without HIV (odds ratio 1.46, 95% CI 1.05–2.03).15 A global meta-analysis put the figure at 47%.15 Roughly half.

The explanatory framework researchers use is minority stress: the cumulative load of living in an environment that is hostile or conditionally accepting. It operates at several levels at once — external events like rejection, harassment, discrimination, and violence; the ongoing vigilance of anticipating them; concealment of identity or status; and internalized stigma, where the outside message becomes the inside voice. For gay and bi men living with HIV, two stigmas stack: sexual-minority stigma and HIV stigma, and studies consistently find internalized HIV stigma is the mediator that carries the effect through to depression.

The practical consequences are not abstract. Depression is one of the strongest predictors of missed appointments and interrupted treatment. Untreated depression makes it harder to start PrEP and harder to stay on it. Concealment predicts isolation, and isolation predicts everything else getting worse. For bisexual men in particular, having no community that fully claims you — often excluded from straight spaces and dismissed in gay ones — is its own distinct stressor, and it is badly under-served by programs designed around a gay identity.

What helps, and is worth asking for by name: therapy with someone who is affirming rather than merely tolerant, and ideally HIV-literate; treatment for depression and anxiety in their own right rather than as an afterthought to viral suppression; peer support and long-term-survivor groups, where the thing you do not have to explain is most of the conversation; and integrated care, since Ryan White–funded clinics can often provide behavioral health on site. If substance use and depression are entangled — which is common, not shameful — say so, because treating one without the other tends to fail. Our mental health and HIV page goes further, and if you are in crisis, 988 is the national Suicide and Crisis Lifeline, with an LGBTQ+ option available by pressing 3.

Aging with HIV — hearts, bones, and the REPRIEVE result

The largest single change in the HIV population is that it is old. More than half of people living with diagnosed HIV in the U.S. are now 50 or older, and 896,231 of the 1,158,701 people living with diagnosed HIV at the end of 2024 were male.1 For a generation of gay and bi men who planned their thirties around dying, aging is both a victory and an unrehearsed problem.

Treatment works, and something else is also true: chronic low-level inflammation and immune activation persist even with a fully suppressed viral load, raising the risk of cardiovascular disease, bone loss, kidney disease, some cancers, and frailty at earlier ages than in the general population. Long-term exposure to older antiretrovirals adds to that picture, and high rates of smoking add more.

REPRIEVE — the trial that changed prevention for people over 40

REPRIEVE randomized 7,769 people living with HIV, aged 40 to 75, on antiretroviral therapy and at low to moderate traditional cardiovascular risk, to daily pitavastatin or placebo. It was stopped early for efficacy at a median 5.1 years of follow-up. Major adverse cardiovascular events occurred at 4.81 per 1,000 person-years on pitavastatin versus 7.32 on placebo — a 35% reduction (hazard ratio 0.65; 95% CI 0.48–0.90), with a 21% reduction in the combined endpoint of cardiovascular events or death.16

Two details make this a landmark rather than a footnote. First, the benefit was larger than the LDL cholesterol drop alone would predict, which supports the idea that HIV-associated inflammation is itself a treatable cardiovascular driver. Second, these were people whose standard risk scores said they did not need a statin. That is why guidelines now lean toward statin therapy for people living with HIV over 40 even at modest calculated risk — and why "should I be on a statin?" belongs at your next visit if you are over 40 and not on one.

The rest of the aging checklist is unglamorous and effective: blood pressure at every visit; lipids and A1c on schedule; bone density screening, since low bone mineral density is more common and more consequential here; kidney function, especially on tenofovir-containing regimens; age-appropriate cancer screening including anal cancer screening where available, because anal HPV-related cancer rates are substantially elevated among gay and bi men living with HIV; and a real conversation about tobacco, which now costs more years of life expectancy in this population than HIV does. See aging with HIV and kidney health.

Why the disparities exist — and what Millett proved

Here is where the "high-risk" framing does the most damage, and where the evidence most decisively refutes it.

In 2012, Millett and colleagues published a meta-analysis in The Lancet pooling 194 studies from the United States, Canada, and the United Kingdom, comparing Black gay and bi men with gay and bi men of other races. If the enormous disparity in HIV prevalence were caused by behavior, this is where it would show up. It did not.17

• Black gay and bi men were equally likely to report condomless sex with a partner of different HIV status.17
• They were less likely to have a substance-use history (U.S. odds ratio 0.67; 95% CI 0.50–0.92).17
• They were more likely to report protective and preventive behavior overall (odds ratio 1.39; 95% CI 1.23–1.57).17
• And yet they were three times as likely to be living with HIV (U.S. odds ratio 3.00; 95% CI 2.06–4.40).17

What did differ was everything structural. Black gay and bi men had roughly twice the odds of unemployment, low income, prior incarceration, and less education, were less likely to have health insurance, and — critically — were less likely to have started combination antiretroviral therapy (U.S. odds ratio 0.40; 95% CI 0.26–0.62), less likely to have a high CD4 count, and less likely to be virally suppressed.17 The authors' conclusion was unambiguous: these disparities cannot be eliminated without addressing structural barriers and access to clinical care.17

Add the network mechanism and the arithmetic closes. HIV moves through sexual networks, and networks are shaped by segregation, incarceration, and who is available to date. If prevalence within a network is already high, an individual can make the same choices as someone in a lower-prevalence network and face a much higher probability of exposure. That is epidemiology, not behavior.

PrEP is where the inequity is now most visible

Prevention has not been distributed the way the epidemic is. On 2023 national data, Black people accounted for 39% of new HIV diagnoses but only 14% of PrEP users, while White people accounted for 24% of diagnoses and 64% of PrEP users. The South accounted for 53% of diagnoses and 39% of PrEP users. Most starkly, in the South there were about 27 White PrEP users for every new diagnosis among White people, versus 5 Black PrEP users for every new diagnosis among Black people.18 CDC's own coverage estimates told the same story: roughly 94% of White people who could benefit from PrEP had been prescribed it, versus about 13% of Black people and 24% of Hispanic/Latino people.18

Awareness is not the gap. Surveys have found PrEP awareness above 85% across racial groups; what diverged was whether a provider ever discussed it and whether the person could actually get it. That is a health-system failure with a known address — and it is why lenacapavir's rollout is being watched so closely. A twice-yearly shot could either close this gap dramatically or reproduce it at a higher price point, depending entirely on who gets access.

The limits of "MSM" — trans men, bi men, and who gets counted

A word about the category itself, because it shapes what the data on this page can and cannot tell you.

"Men who have sex with men," and CDC's surveillance term male-to-male sexual contact, are epidemiological categories describing behavior, not identities.1 That design choice was deliberate and useful: it captures men who have sex with men without requiring them to identify as gay or bisexual, which matters for men married to women, men in communities where a gay identity is dangerous, and men who simply do not use those words about themselves. But it comes with real costs.

It flattens bisexual men. Bi men appear in the data only through their male partners, which makes their lives, relationships, and prevention needs invisible — and feeds the wrong idea that bisexuality is a way station rather than an orientation. Bi men have distinct needs and distinctly poor service coverage.

It handles trans people badly. Transgender women are not men and are not "MSM," though older data sets sometimes coded them that way, which corrupted both trans women's and gay men's numbers for years. Surveillance practice has improved, and trans women are now reported separately — see HIV and transgender women. Transgender men are the group most often left out entirely. Trans men who have sex with cisgender men share network exposure with gay and bi cis men, may need PrEP, often need sexual-health care clinics are not set up to provide, and are routinely excluded from both "MSM" and women's health programming. If you are a trans man reading this, the prevention science here applies to you; the details of your care should come from a provider who knows trans health.

It says nothing about culture. A 24-year-old Black gay man in Jacksonville, a 58-year-old White long-term survivor in St. Petersburg, a Haitian immigrant in Miami, and a married man in a rural county who has never said the word "gay" out loud are all one line in a surveillance table. They need four different programs. See HIV and LGBTQ+ communities.

Dating, disclosure, and mixed-status relationships

The hookup apps that organize much of gay sexual life now also organize much of gay HIV stigma. Profiles still read "clean only" and "DDF" — language that codes people living with HIV as dirty and belongs in the past. If you have been on the receiving end of it, the problem is the profile, not you.

You get to decide when to disclose. There is no ethical rule requiring disclosure to every match. What you owe someone is honesty as intimacy develops, not a status announcement to strangers. Many people find a straightforward, unapologetic script easiest: "I'm living with HIV, I'm on treatment, and my viral load is undetectable — which means I can't pass it on." That sentence is accurate and does the informing and the reassuring at once.6

Know your state's law before you decide how to handle it. Disclosure is not only interpersonal. More than thirty states have HIV-specific criminal statutes, many written before effective treatment existed and many not requiring transmission or even a realistic possibility of it. Florida has such a law. See HIV criminalization in Florida and stigma and disclosure.

Mixed-status couples are ordinary. With sustained suppression, or with the HIV-negative partner on PrEP, or both, transmission risk within the couple is effectively zero.67 Belt and suspenders is a reasonable choice, and so is either one alone. Many couples find the conversation gets easier once both partners read the PARTNER numbers themselves rather than taking them second-hand.

Rejection will still happen. Some people will decline for reasons that are really about fear or misinformation, and it will hurt regardless of how well you understand the science. It is also information: someone unable to hear "undetectable" as "untransmittable" is telling you how they will handle other hard things. Our relationships page has more, and community publications like POZ and TheBody have decades of first-person writing from gay and bi men who have navigated exactly this.

Stigma — internal, medical, and legal

Stigma is not a feeling. It is a set of mechanisms with measurable effects on testing, treatment, and survival, and it operates in at least three places.

Internalized. The most expensive and least visible. It shows up as not calling the clinic, not filling the prescription, not telling a partner, not going back after a missed appointment, and a running commentary that says you deserved this. It responds to therapy and peer contact — being in a room with other people living with HIV who are living well beats any pamphlet.

Medical. Being asked how you "got it" in a tone that expects an apology. Double-gloving. A chart note that reads as a judgment. Dental offices that will not schedule you, which is illegal under the Americans with Disabilities Act and still happens — see HIV and dental care. You are allowed to change providers, and Ryan White clinics and LGBTQ+ health centers are usually the most practiced at getting this right.

Legal and structural. HIV-specific criminal laws, immigration consequences, housing discrimination, and employment discrimination are all documented and all actionable. The Sero Project, Lambda Legal, and the Center for HIV Law and Policy work in this area; our criminalization and housing pages have more.

The through-line from the Denver Principles still holds: the people most affected are the ones who know what needs to change, and the language used about you is not a neutral detail.5 That is why this site says "person living with HIV" and never "victim" — see language matters and shame and stigma.

Florida — seven priority counties and an ADAP year nobody should forget

Florida is where the national numbers get concrete, and it carries more federal HIV priority counties than any other state. Of the 57 Phase 1 jurisdictions in the federal Ending the HIV Epidemic initiative, seven are Florida counties: Broward, Duval, Hillsborough, Miami-Dade, Orange, Palm Beach, and Pinellas.19 Preliminary CDC indicators put 2024 diagnoses at 1,047 in Miami-Dade, 551 in Broward, 426 in Orange, 332 in Palm Beach, 277 in Hillsborough, 254 in Duval, and 158 in Pinellas.19 Florida's HIV-related death rate, 2.8 per 100,000, was among the five highest in the nation in 2024.1

Two Florida patterns matter for gay and bi men specifically. Diagnoses attributed to male-to-male sexual contact are the largest transmission category in the state, and Hispanic/Latino men make up a growing share of them — a demographic reality that outreach in English only will never reach. And Florida's epidemic is metropolitan and coastal in its counts, but rural in its access gaps; see rural Florida.

The 2026 ADAP whiplash

Anyone in Florida who relies on the AIDS Drug Assistance Program lived through something in 2026 worth naming precisely, because it explains why many people are wary of the system right now.

Facing a reported federal shortfall, the Florida Department of Health announced in January 2026 and implemented on March 1, 2026 a set of cuts: income eligibility dropped from 400% to 130% of the federal poverty level — roughly $63,840 down to $20,748 for a household of one — insurance premium assistance was eliminated, and Biktarvy, the most widely prescribed HIV medication in the country, was pulled from the formulary. More than 12,000 Floridians were affected out of 27,638 enrollees.20

The Legislature reversed it, unanimously and on a bipartisan basis. An amendment to House Bill 697 appropriated $30.9 million in bridge funding through June 30, restored eligibility to 400% FPL, and required monthly financial reporting from the Department of Health beginning April 1.20 The FY 2026–27 state budget then made the restoration durable. As of July 1, 2026, the Department of Health states that eligibility is 0–400% FPL, that direct-dispense medication assistance is available to uninsured Floridians in that range, that copay and deductible assistance continues for insured clients through CVS Caremark, and that both Biktarvy and Descovy have been restored to the formulary for direct-dispense and retail-dispense clients alike.20 Our Florida ADAP changes page tracks this in detail.

What to do next

Whatever brought you here, there is a next step that is smaller than the whole problem.

If you do not have HIV and you are not on PrEP, pick one of the four options and ask for it by name. If a daily pill has not worked for you, say that — Apretude and Yeztugo exist precisely because daily dosing does not fit everyone.910 If you have had a bacterial STI in the last year, ask about doxy-PEP in the same visit.12 Cost is negotiable more often than people assume; ask before you rule anything out.

If you do not know your status, test. Self-test kits are mailed free in much of the country, and a reactive result is the beginning of treatment, not the end of anything.3 See HIV testing.

If you were diagnosed recently, the sequence is start treatment, get a viral load, get a case manager. Modern regimens are usually one pill daily with few side effects, and most people reach an undetectable viral load within one to six months. Your life expectancy is normal, and once suppressed you will not transmit the virus.6 Go to newly diagnosed.

If you fell out of care, come back. Nobody at a Ryan White clinic is keeping score, and re-engagement is one of the most routine things they do. See re-engaging in care.

If you are over 40 and living with HIV, ask about a statin at your next visit, and ask what your cardiovascular risk assessment actually said.16 Ask about bone density and anal cancer screening too.

If the hardest part right now is your head, not your labs, that is the most common experience in this article and the one most worth treating. Depression affects roughly four in ten gay and bi men living with HIV, and it is treatable.15 Start at mental health and HIV, or call 988 and press 3.

Forty-plus years in, this community built the model that global health now uses: refuse the label, learn the science, demand the trial, share the result. The Denver Principles were written by people who were told they were dying and who insisted on the word "living" anyway.5 That is still the assignment.